BR112023001145A2 - Composto tendo atividade inibitória de quinase - Google Patents

Composto tendo atividade inibitória de quinase

Info

Publication number
BR112023001145A2
BR112023001145A2 BR112023001145A BR112023001145A BR112023001145A2 BR 112023001145 A2 BR112023001145 A2 BR 112023001145A2 BR 112023001145 A BR112023001145 A BR 112023001145A BR 112023001145 A BR112023001145 A BR 112023001145A BR 112023001145 A2 BR112023001145 A2 BR 112023001145A2
Authority
BR
Brazil
Prior art keywords
inhibitory activity
compound
kinase inhibitory
present
kinase
Prior art date
Application number
BR112023001145A
Other languages
English (en)
Inventor
Wu Haiping
Wang Meng
Mi Yuan
Fu Xingnian
Shi Hui
Guo Jiannan
Original Assignee
Cytosinlab Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosinlab Therapeutics Co Ltd filed Critical Cytosinlab Therapeutics Co Ltd
Publication of BR112023001145A2 publication Critical patent/BR112023001145A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO TENDO ATIVIDADE INIBITÓRIA DE QUINASE. A presente invenção fornece compostos tendo atividade inibitória de quinase. Especificamente, a presente invenção fornece compostos tendo uma estrutura representada pela seguinte fórmula (II). O composto da presente invenção apresenta boa atividade inibitória para uma variedade de quinases (por exemplo, ALK, AXL, EGFR, e FLT3) e, portanto, pode ser usado para preparar uma composição farmacêutica para tratamento de doenças relacionadas à atividade de quinase (por exemplo, leucemia mieloide aguda, etc.).
BR112023001145A 2020-07-23 2021-07-22 Composto tendo atividade inibitória de quinase BR112023001145A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010718607 2020-07-23
CN202110172680 2021-02-08
PCT/CN2021/107759 WO2022017434A1 (zh) 2020-07-23 2021-07-22 一类具有激酶抑制活性的化合物

Publications (1)

Publication Number Publication Date
BR112023001145A2 true BR112023001145A2 (pt) 2023-04-04

Family

ID=79586294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001145A BR112023001145A2 (pt) 2020-07-23 2021-07-22 Composto tendo atividade inibitória de quinase

Country Status (9)

Country Link
US (1) US20230339936A1 (pt)
EP (1) EP4186901A4 (pt)
JP (1) JP2023535096A (pt)
KR (1) KR20230043955A (pt)
CN (1) CN113968856B (pt)
AU (1) AU2021314416A1 (pt)
BR (1) BR112023001145A2 (pt)
CA (1) CA3186758A1 (pt)
WO (1) WO2022017434A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型
WO2023143344A1 (zh) * 2022-01-30 2023-08-03 微境生物医药科技(上海)有限公司 新型egfr抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2553785C (en) * 2004-02-14 2011-02-08 Irm Llc Compounds and compositions as protein kinase inhibitors
US20070004763A1 (en) * 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
WO2018035072A1 (en) * 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CN110944994B (zh) * 2017-08-21 2023-06-09 默克专利股份公司 作为腺苷受体拮抗剂的喹喔啉衍生物
MX2020003732A (es) * 2017-09-28 2021-06-29 Cstone Pharmaceuticals Suzhou Co Ltd Derivado de anillo fusionado como inhibidor del receptor a2a.

Also Published As

Publication number Publication date
KR20230043955A (ko) 2023-03-31
CN116323562A (zh) 2023-06-23
EP4186901A4 (en) 2024-06-12
CN113968856A (zh) 2022-01-25
US20230339936A1 (en) 2023-10-26
JP2023535096A (ja) 2023-08-15
AU2021314416A1 (en) 2023-02-23
CA3186758A1 (en) 2022-01-27
WO2022017434A1 (zh) 2022-01-27
EP4186901A1 (en) 2023-05-31
CN113968856B (zh) 2023-09-26

Similar Documents

Publication Publication Date Title
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
BR112023001145A2 (pt) Composto tendo atividade inibitória de quinase
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
CL2021003012A1 (es) Inhibidores del inflamasoma nlrp3
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CY1120179T1 (el) Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BR112022025613A2 (pt) Novo inibidor de secreção de ácido e uso do mesmo
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
BR112021019465A2 (pt) Compostos que têm como alvo prmt5
BR112022019492A2 (pt) Inibidores de rip1k
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BR112021020241A2 (pt) Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
BR112022009103A2 (pt) Compostos heterocíclicos fungicidas inovadores contendo sulfiliminas ou sulfoximinas
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.